Cancer Treatment Reviews 115(2023)102541Contents lists available at ScienceDirectCNC田TREATMENTREVEWSCancer Treatment ReviewsELSEVIERjournal homepage:www.elsevier.com/locate/ctrvTumour ReviewEuropean expert panel consensus on the clinical management ofBRAFV600E-mutant metastatic colorectal cancerErika Martinelli,Dirk Amold,Andres Cervantes,Sebastian Stintzing,Eric Van Cutsem,Josep Tabernero,Julien Taieb Harpreet Wasan',Fortunato CiardielloDepartment of Precision Medicine,Division of Medical Oncology,University of Campania Luigi Vanvitelll 80131 Naples,ItalyDepartment of Oncology and Hematology,Askepios Tumorzentnim Hamburg AK Alona Hamburg.GermanyDeparment of Medical Oncology,INCLIVA Biomedical Research Instinte,Universiry of Valenda,Valenda,Spaind CBERONG Instntto de Sabd Carlos III,Madrid,SpainDepartment of Hematology,Oncology,and Cancer Immmology (CCM),Charite -Universitoetsmnedtin Berlin,10117 Berlin,Germanys Department of Medicl Oncology,Vall d'Hebron Hospital Campus and Vall d'Hebron Instintte of Oncology (VHIO),OB-Quron 08035 Barcelona,SpainDepartment of Gastroenterology and GI Onclogy,Georges Pompidou European Hospital Assimance Publique-Hpisux de Paris AP-HP Paris Centre,Universie ParisC,SIRIC CARPEM,Paris FranceDeparmnent of Cancer Medicine,Hammersmith Hospisl,Imperial College Healthcare NHS Tnst,London W12 OHS,UKDeparment of Precision Medicine,Division of Medionl Oncology,University of Campania,Luigi Vanvitelli 80131 Naples,ItalyARTICLE INFOABSTRACTKeywords:Metastatic colorectal cancer (mCRC)is a heterogenous disease caused by various genetic alterations.TheMetastatic colorectal cancerBRAF mutation occurs in approximately 81%of patients and is characterised by an aggressive clinicalBRAFcourse and poor prognosis.Here we review the current knowledgeon BRAmutant mCRC and provide aConsensusTreatmentseries of consensus statements on its dinical management.The treatment landscape for BRAmutant mCRChas changed greatly due to the emergence of molecular targeted therapies (including BRAF inhibitors)andimmune checkpoint inhibitors.A scientific literature search identified available data on molecular testing,treatments,and clinical monitoring of patients with BRAmutant mCRC.Consensus statements were dis-dnd developed by a Europxprpanel.Thismnip providesmnement guidancefordifferent clinical presentations of BRAF-mutant mCRC and makes recommendations regarding treatmentsequencing choices.To guide appropriate clinical management and treatment decisions for mCRC patients,tumour tissue analysis for DNA mismatch repair/microsatellite status and,at a minimum,KRAS,NRAS,andBRAF mutational status is mandatory at the time of diagnosis.Finally,we discuss the rapidly evolving treatmentlandscape for BRAmutant mCRC and define priorities for the development of novel therapeutic strategiesthat are needed to improve patient outcomes.IntroductionAlthough the prognosis of patients with metastatic CRC (mCRC)hasimproved greatly in recent years due to the introduction o
